Blog Layout

Cancer deaths reduce Australia wide
Sep 16, 2020

This year the annual release of cancer statistics generated quite a buzz in the cancer community.

We have seen an ongoing and significant decline in the overall number of cancer deaths through Australia. Improvements in the number of deaths from lung cancer, which account for more cancer deaths than breast, prostate and colorectal cancer combined, was the main driver for this decline.


There are many possible contributors to this, perhaps the most important being the impact of improved tobacco control and a decline in the number of individuals taking up smoking. However, in addition to a decrease in the number of people being diagnosed with lung cancer there has also been a significant improvement in our treatment of lung cancer and therefore the number of deaths from this disease. So much so that the current treatment for lung cancer was not used even 2 years ago and continues to rapidly evolve on a month-to-month basis.


The main change to lung cancer treatment is the addition of new drugs to our treatment regimens of non-small cell lung cancer. There are now a range of different anti-cancer drugs which are used to treat metastatic (advanced) lung cancer. Currently, this type of lung cancer is not curable. The aim of treatment for advanced lung cancer is control of the disease and this control has been improved with the introduction of immunotherapy drugs including pembrolizumab (Keytruda), nivolumab (Opdivo) and atezolizumab (Tecentriq) either alone or with chemotherapy.


Clinical trials have shown that one or a combination of drugs improved the survival of patients with lung cancer compared to chemotherapy alone. Deciding between and tailoring treatment options needs to take into account an individual’s age, fitness and their own priorities as well as specific attributes of the cancer including size, stage and type of cancer cell involved. The oncologists at Ballarat Cancer Care and Haematology have extensive experience in the treatment of lung cancer, including involvement in clinical trials and multi-disciplinary meetings both in Ballarat and Melbourne.


4th Dose COVID-19 Vaccine for Immunocompromised Patients
01 Mar, 2022
The Australian Technical Advisory Group on Immunisation (ATAGI) has approved a fourth dose of a COVID-19 vaccine for people with weakened immune systems. People aged 18 years or older with weakened immune system who received a 3-dose primary course of the COVID-19 vaccine are now recommended to receive the fourth dose ≥ 3 months after their third dose. This is expected to improve protection against symptomatic infection, serious illness, or death from COVID-19 infection.
COVID-19 Vaccine Booster Shots In Our Patients With Cancer
08 Nov, 2021
The Government and the Medical advisory group (ATAGI) have release new recommendations last week for individuals who are severely immunocompromised in regards to the COVID-19 vaccine. These recommendations will affect some (but not all) of our patients. As always, we are happy to discuss any of the recommendations further with all of our patients.
COVID-19 Vaccination FAQs July 2021
20 Jul, 2021
In the last few months, I have been inundated with many questions regarding COVID-19 vaccination and blood clots from patients and other health practitioners. In this article, I have compiled these frequently asked questions.
New PBS listings!
02 Jul, 2021
Despite a global pandemic, new data relating to oncology treatments continues to be published, and it seems that this is increasingly translating into improved drug access here in Australia.
Astra Zeneca (AZ) vaccine safety information
26 Mar, 2021
In light of recent reports of clotting events following Astra Zeneca (AZ) vaccine in Europe - we have been frequently asked questions regarding the safety of AZ vaccine in patients with previous clot events and/or blood problems
25 Feb, 2021
Two vaccines against the coronavirus have now been approved for use in Australia, role-out of the vaccine begins this week in high-risk populations.
18 Jan, 2021
Dr Swe Myo Htet Consultant Haematologist MBBS, FRACP, FRCPA, MRCP
Blood clot disorder and long distance car-travel
02 Dec, 2020
Blood specialist, Dr. Pohan Lukito, answers frequently asked question regarding blood clot disorder and long distance car-travel
Exercise and Cancer
26 Oct, 2020
Patients with a malignancy, and in particular those receiving treatment for a malignancy, often experience fatigue. And while adequate rest is important, there has been increasing evidence over the past few years that a regular exercise programme can have a considerable benefit on this fatigue, as well and many other treatment related side effects.
13 Oct, 2020
Today (13th Oct) is World Thrombosis Day. We are raising awareness of blood clotting disorders - please find this informative article written by Dr Swe Htet. Patients - you can refer to educational material written by Thrombosis & Haemostasis society of Australia and New Zealand (THANZ) - Preventing another clot (download PDF here) More information regarding thrombosis from THANZ https://www.thanz.org.au/educationandtraining/education-training Clinicians/GPs - you can refer to the Thrombosis Quick Guide developed by our haematologists to help you manage patients with thrombosis (download PDF here) ---------------------------- 1 in 4 people are dying from conditions caused by thrombosis. Blood clotting is a biological plumber fixing a leaking blood vessel. Blood clot will save your life from bleeding if you have a cut in your finger. However, if a blood clot forms unnecessarily in blood vessels called thrombosis, it can lead to significant medical issues. Thrombosis can develop either in the arteries or veins. If there is a clot in an artery supplying the brain, that part of the brain will die leading to stroke. The same principle applies for heart attack when there is a blood clot in the coronary arteries supplying blood to the heart. Whilst many people are aware of the signs and symptoms of a heart attack or stroke, the symptoms of blood clot in the veins can be more difficult to recognized, leading to delayed presentation and treatment. Blood clot forming in the deep veins of the legs is called deep vein thrombosis (DVT). Whilst DVT in the lower limbs is not usually life-threatening, if a large clot breaks off and travels to the lung(s), it can cause blockage of blood flow into the lung(s) causing pulmonary embolism (PE) that can be extremely dangerous to patients. Symptoms of DVT in the legs can be pain, swelling or redness in the calf. Patients can present with palpitation, chest pain, and shortness of breath if there is PE. There are three main risk factors for thrombosis in the veins - immobility, sticky blood, and changes in the lining of the veins. These risks could be acquired, such as immobility during long distance travel (flights) and patients lying in bed following surgery, or specific conditions e.g. cancer that could cause blood to be “more sticky”. However, some of the risks could also be familial (passed down from families). Please speak to your doctor regarding these risks if you are concerned. These are quite different to the risk factors of arterial thrombosis; which are mainly smoking, high cholesterol, diabetes, and hypertension. Venous thrombosis can be treated with blood thinning agents. Different blood thinning agents used for venous thrombosis include Warfarin, Clexane, and more recently - Rivaroxaban and Apixaban. Main complication of blood thinning agent is bleeding. The choice and duration of blood thinning agent varies among different individuals. Please discuss this with your doctor. Blood Specialists at Ballarat Cancer Care and Haematology will be available to have further conversation regarding management of blood clots. ~ Article written by Dr Swe Htet
More Posts
Share by: